Key points
- 1Health and Human Services Department published the official notice “Determination of Regulatory Review Period for Purposes of Patent Extension; TRYVIO.” Health and Human Services Department published the official notice “Determination of Regulatory Review Period for Purposes of Patent Extension; Symplicity Spyral Renal Denervation System.” The legal effect of those events depends on their distinct posture, not their shared appearance in a monthly feed.[1][2]
- 2FDA’s patent-term-extension review-period determinations for two regulated products illustrate an IP issue created outside the patent office. Product approval dates, diligence, and the statutory extension record must be coordinated with prosecution and lifecycle strategy.[1][2]
- 3The response should begin with a verifiable record of the authority that actually governs the matter, the operational facts, the accountable decision maker, and any event that requires the analysis to be refreshed. The background authorities collected here are context, not a conclusion that each governs every monthly development.[3][4]
January 2026: the record in view
The first in-window anchor is “Determination of Regulatory Review Period for Purposes of Patent Extension; TRYVIO,” issued by Health and Human Services Department. The second is “Determination of Regulatory Review Period for Purposes of Patent Extension; Symplicity Spyral Renal Denervation System,” issued by Health and Human Services Department. Read together, they show the range of instruments, enforcement postures, and—where present—judicial authority that can shape this practice area during a single month.[1][2]
Neither a publication title nor an agency summary should be asked to carry more weight than its posture permits. A proposed action is not a final rule; a charging document states allegations; a settlement resolves a matter on negotiated terms; and a notice may initiate, explain, or complete only the procedure it identifies.[1][2]
The legal significance
FDA’s patent-term-extension review-period determinations for two regulated products illustrate an IP issue created outside the patent office. Product approval dates, diligence, and the statutory extension record must be coordinated with prosecution and lifecycle strategy.[1][2]
FDA issued notices determining the regulatory-review periods for the drug TRYVIO and the Symplicity Spyral renal-denervation device in connection with patent-term-extension applications. Those determinations supply inputs to the Patent Office’s statutory extension analysis; they do not themselves grant an extension or decide its ultimate length.[1][2]
The recurring issue is evidentiary: an organization may understand the commercial value of an asset yet still lack the contemporaneous record needed to establish inventorship, entitlement, prosecution compliance, or license scope. The selected statutory, regulatory, or policy materials below provide background for recurring issues in this practice area; they may not govern every monthly development. Counsel must identify the operative authority for the particular facts before advising on scope, duties, or relief.[1][2][3][4]
A disciplined operating response
IP governance should integrate invention intake, contributor analysis, assignment, prosecution decisions, government-rights screening, and transaction diligence rather than treating them as separate legal workstreams.[1][3][4]
- Require contribution records that distinguish problem framing, technical conception, experimentation, and validation.[1][3]
- Screen funding, employment, collaboration, and public-sector constraints before prosecution or licensing decisions.[2][4]
- Tie diligence conclusions to the underlying chain of title, filing record, and operative license language.[1][2]
What to watch next
Monitor whether the source is a procedural notice, licensing opportunity, proposed requirement, enforcement announcement, or adjudicated result. Those categories support materially different conclusions about rights and risk.[1][2]
This January 2026 edition is an issue-spotting record, not a representation that every relevant authority was captured. The accepted ingest covered Federal Register and DOJ materials for the calendar month; case-law discovery, historical eCFR changes, dockets, corporate filings, and state sources remain subject to the limitations stated on this page.[1][2]